Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2020 657
2021 1020
2022 269
Text availability
Article attribute
Article type
Publication date

Search Results

1,753 results
Results by year
Filters applied: . Clear all
Page 1
How should we use convalescent plasma therapies for the management of COVID-19?
Wood EM, Estcourt LJ, McQuilten ZK. Wood EM, et al. Blood. 2021 Mar 25;137(12):1573-1581. doi: 10.1182/blood.2020008903. Blood. 2021. PMID: 33202419 Free PMC article. Review.
Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune
Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benef
Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
Wang Y, Huo P, Dai R, Lv X, Yuan S, Zhang Y, Guo Y, Li R, Yu Q, Zhu K. Wang Y, et al. Int Immunopharmacol. 2021 Feb;91:107262. doi: 10.1016/j.intimp.2020.107262. Epub 2020 Dec 5. Int Immunopharmacol. 2021. PMID: 33338863 Free PMC article.
Convalescent plasma(CP) immunotherapy was an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. ...METHODS: A literature search was conducted on Pubmed, Cochrane Library, Clinical Key, Wanfang Database
Convalescent plasma(CP) immunotherapy was an effective method for fighting against similar viral infections such as SARS
Emerging treatment strategies for COVID-19 infection.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Clin Exp Med. 2021 May;21(2):167-179. doi: 10.1007/s10238-020-00671-y. Epub 2020 Oct 30. Clin Exp Med. 2021. PMID: 33128197 Free PMC article. Review.
The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused by SARS-CoV-2 characterized as atypica …
The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and has led to a worldwid …
An update of anti-viral treatment of COVID-19.
Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI. Şimşek-Yavuz S, et al. Turk J Med Sci. 2021 Dec 17;51(SI-1):3372-3390. doi: 10.3906/sag-2106-250. Turk J Med Sci. 2021. PMID: 34391321 Free PMC article. Review.
We aimed to review and summarize all of the current knowledge on the antivirals for COVID-19 RESULTS: There are 2 main drug groups for SARS-CoV-2: agents that target proteins or RNA of the virus or interfere with proteins or biological pr …
We aimed to review and summarize all of the current knowledge on the antivirals for COVID-19 RESULTS: There are 2 main …
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.
O'Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, Philip NM, Cheung YK, Gupta V, João E, Pilotto JH, Diniz MP, Cardoso SW, Abrams D, Rajagopalan KN, Borden SE, Wolf A, Sidi LC, Vizzoni A, Veloso VG, Bitan ZC, Scotto DE, Meyer BJ, Jacobson SD, Kantor A, Mishra N, Chauhan LV, Stone EF, Dei Zotti F, La Carpia F, Hudson KE, Ferrara SA, Schwartz J, Stotler BA, Lin WW, Wontakal SN, Shaz B, Briese T, Hod EA, Spitalnik SL, Eisenberger A, Lipkin WI. O'Donnell MR, et al. J Clin Invest. 2021 Jul 1;131(13):e150646. doi: 10.1172/JCI150646. J Clin Invest. 2021. PMID: 33974559 Free PMC article. Clinical Trial.
Patients were randomized 2:1 to receive a single transfusion of either convalescent plasma or normal control plasma. ...The median titer of anti-SARS-CoV-2 neutralizing antibody in infused convalescent plasma units wa …
Patients were randomized 2:1 to receive a single transfusion of either convalescent plasma or normal control plasma
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.
Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, Grossman BJ, Henderson JP, Musser J, Salazar E, Hartman WR, Bouvier NM, Liu STH, Pirofski LA, Baker SE, van Helmond N, Wright RS, Fairweather D, Bruno KA, Wang Z, Paneth NS, Casadevall A, Joyner MJ. Klassen SA, et al. Mayo Clin Proc. 2021 May;96(5):1262-1275. doi: 10.1016/j.mayocp.2021.02.008. Epub 2021 Feb 17. Mayo Clin Proc. 2021. PMID: 33958057 Free PMC article. Review.
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. ...Additional a …
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 …
Convalescent plasma and hyperimmune globulin therapy in COVID-19.
Cagdas D. Cagdas D. Expert Rev Clin Immunol. 2021 Apr;17(4):309-316. doi: 10.1080/1744666X.2021.1894927. Epub 2021 Mar 12. Expert Rev Clin Immunol. 2021. PMID: 33620014 Review.
Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. ...This review discusses the current knowledge on CP and HIG therapies used …
Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID- …
COVID-19 convalescent plasma: Interim recommendations from the AABB.
Cohn CS, Estcourt L, Grossman BJ, Pagano MB, Allen ES, Bloch EM, Casadevall A, Devine DV, Dunbar NM, Foroutan F, Gniadek TJ, Goel R, Gorlin J, Joyner MJ, Metcalf RA, Raval JS, Rice TW, Shaz BH, Vassallo RR, Winters JL, Beaudoin G, Tobian AAR. Cohn CS, et al. Transfusion. 2021 Apr;61(4):1313-1323. doi: 10.1111/trf.16328. Epub 2021 Mar 7. Transfusion. 2021. PMID: 33586160 Free PMC article. Review. No abstract available.
Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.
Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA, Bolouki Moghaddam F, Imanizadeh S, Moeini Maleki M, Ranjkesh M, Rezapour M, Bahramifar A, Einollahi B, Hosseini MJ, Jafari NJ, Nikpouraghdam M, Sadri N, Tazik M, Sali S, Okati S, Askari E, Tabarsi P, Aslani J, Sharifipour E, Jarahzadeh MH, Khodakarim N, Salesi M, Jafari R, Shahverdi S. Abolghasemi H, et al. Transfus Apher Sci. 2020 Oct;59(5):102875. doi: 10.1016/j.transci.2020.102875. Epub 2020 Jul 15. Transfus Apher Sci. 2020. PMID: 32694043 Free PMC article. Clinical Trial.
However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. ...This clinical study provides strong evidence to support the effic …
However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has bee …
A look-back at convalescent plasma to treat COVID-19.
Garraud O, Lacombe K, Tiberghien P. Garraud O, et al. Transfus Apher Sci. 2021 Feb;60(1):103063. doi: 10.1016/j.transci.2021.103063. Epub 2021 Jan 12. Transfus Apher Sci. 2021. PMID: 33478889 Free PMC article. Review. No abstract available.
1,753 results